𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma

✍ Scribed by Maryam Fouladi; Diana Stempak; Janet Gammon; Julia Klein; Ron Grant; Mark L. Greenberg; Gideon Koren; Sylvain Baruchel

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
135 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of paclitaxel, estramusti
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
✍ David C. Smith; Christopher H. Chay; Rodney L. Dunn; Jude Fardig; Peg Esper; Kar πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 127 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Preclinical data suggest that the combination of intravenous (i.v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone‐refractory prostate carcinoma. The authors conducted this clinical trial t

A phase I trial of ifosfamide and paclit
A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors
✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra

A Phase I study of granulocyte-macrophag
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors : A report of the Children's Cancer Group
✍ Mitchell S. Cairo; Mark D. Krailo; Joel A. Weinthal; Rita Secola; Sharon Bergero πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 148 KB πŸ‘ 3 views

## Background: This phase i trial was developed to determine the safety, biologic activity, and effects on hematopoietic recovery of pixy321 following ifosfamide, carboplatin, and etoposide chemotherapy for children with recurrent or refractory solid tumors. ## Methods: Children (age < 22 years a

A phase II trial of combination chemothe
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma : Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist
✍ Jame Abraham; Susan Bakke; Ann Rutt; Beverly Meadows; Maria Merino; Richard Alex πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 130 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Adrenocortical carcinoma (ACC) is rare, nearly always fatal, and to the authors' knowledge has few nonsurgical treatment options. Based on in vitro studies demonstrating the efficacy of mitotane as a P‐glycoprotein (Pgp) antagonist, and expression of high levels of Pgp in

Phase III trial of gemcitabine and carbo
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma
✍ Sarah Danson; Mark R. Middleton; Kenneth J. O'Byrne; Mark Clemons; Malcolm Ranso πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 325 KB

## Abstract ## BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in patients with advanced nonsmall cell lung carcinoma (NSCLC). The primary objective was survival. Secondary objectives we